Skip to content
Clinical Trials – home
Therapeutic area

Immune system disorders – page 125

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Dermatitis atopic

Not recruiting

Study on Dose Flexibility of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness of Mesenchymal Stromal Cells in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Etanercept
  • Sponsor:Medac Gesellschaft fuer klinische Spezialpraeparate mbH

Vitiligo

Not recruiting

Study on the Effects of Ruxolitinib Cream for Patients with Genital Vitiligo

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Lupus nephritis

Not recruiting

Study on Zetomipzomib for Patients with Active Lupus Nephritis

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Kezar Life Sciences Inc.

Dermatitis atopic

Not recruiting

Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of Afimetoran for Patients with Active Lupus

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Afimetoran Besilate Dihydrate

Study on the Effects of Siplizumab in Adults with New Onset Type 1 Diabetes

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Paracetamol
  • Sponsor:Itb-Med AB

Seasonal allergy

Not recruiting

Study on the Effectiveness and Safety of Phleum Pratense Pollen Extract for Patients with Moderate-to-Severe Grass Pollen Allergy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Loratadine
  • Sponsor:ROXALL Medizin GmbH

Colitis ulcerative

Not recruiting

Study on the Effects of GS-5290 for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(Phosphonooxy)Methyln-[(S)-[1-(Bicyclo[1.1.1]Pentan1-Yl)-1H-1,2,3-Triazol-4-Yl](2-Methyl-1-Oxo-1,2-Dihydroisoquinolin-5-Yl)Methyl]-N-{8-Chloro-3-Cyano-4-[(2,2-Dimethylpropyl)Amino]Quinolin-6-Yl]Carbamate
  • Sponsor:Gilead Sciences Inc.

Study of GS-5718 for Patients with Cutaneous Lupus Erythematosus (CLE)

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:GS-5718-03
  • Sponsor:Gilead Sciences Inc.

Study on the Effects of MBS2320 for Patients with Idiopathic Pulmonary Fibrosis (IPF)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:MBS2320
  • Sponsor:Modern Biosciences Limited

Study of PF-06823859 for Adults with Active Cutaneous or Systemic Lupus Erythematosus with Skin Symptoms

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Humanised IGG1K monoclonal antibody against interferon beta
  • Sponsor:Pfizer Inc.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.